America's 10 Highest-Paid CEOs of 2011 (and How They Earned It)
What Happened When Alex Kenjeev Paid His Student Loan in Cash
Sciele Pharma (NASDAQ: SCRX) announced the FDA approved its new formulation of Sular (high blood pressure treatment).
SCRX closed at $19.84 Wednesday.
Friedman BIlings says: "Successful execution of the Sular switch will remain a concern for investors and depress the near-term share valuation."
SCRX January option implied volatility of 82 is above its 26-week average of 48 according to Track Data, suggesting larger risk.
Options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
